Nucleic acid-polypeptide compositions and uses thereof
US-10550188-B2 · Feb 4, 2020 · US
Anti-transferrin receptor antibodies and uses thereof
US11827702B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11827702-B2 |
| Application number | US-202217900161-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 31, 2022 |
| Priority date | Sep 1, 2021 |
| Publication date | Nov 28, 2023 |
| Grant date | Nov 28, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of their use. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.
First claim
Opening claim text (preview).
What is claimed is: 1. An antibody that binds to human transferrin receptor, comprising a heavy chain variable region (VH) comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein the antibody comprises a light chain variable region (VL) comprising VL CDR1, VL CDR2, and VL CDR3, and wherein the VH CDR1 comprises the amino acid sequence GIDFSSSGYMC (SEQ ID NO:101), the VH CDR2 comprises the amino acid sequence CIYTYSSNTYYAASVKG (SEQ ID NO:103), the VH CDR3 comprises the amino acid sequence GTYGYTGYTYTMGYFSL (SEQ ID NO:106), the VL CDR1 comprises the amino acid sequence QASQNINSYLA (SEQ ID NO:107), the VL CDR2 comprises the amino acid sequence RASSLES (SEQ ID NO:108), and the VL CDR3 comprises the amino acid sequence QSYYYSGSSNYNA (SEQ ID NO:110). 2. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. 3. A conjugate comprising the antibody of claim 1 . 4. The antibody of claim 1 , which is an Fab fragment or an Fab′ fragment. 5. An antibody that binds to human transferrin receptor, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence of SEQ ID NO:16 and the VL comprises the amino acid sequence of SEQ ID NO:35. 6. The antibody of claim 5 , which is an Fab fragment or an Fab′ fragment. 7. A pharmaceutical composition comprising the antibody of claim 5 and a pharmaceutically acceptable carrier. 8. A conjugate comprising the antibody of claim 5 . 9. An antibody that binds to human transferrin receptor, comprising a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:95, and a light chain comprising the amino acid sequence set forth in SEQ ID NO:96. 10. A pharmaceutical composition comprising the antibody of claim 9 and a pharmaceutically acceptable carrier. 11. A conjugate comprising the antibody of claim 9 .
Assignees
Inventors
Classifications
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Complementarity determining region [CDR] · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11827702B2 cover?
- The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of their use. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.
- Who is the assignee on this patent?
- Biogen Ma Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2881. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).